相似文献
1
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.
Genes Dev. 2012 Jan 15;26(2):120-5. doi: 10.1101/gad.182980.111.
2
Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Cell Death Differ. 2019 Jul;26(7):1316-1331. doi: 10.1038/s41418-018-0209-1. Epub 2018 Nov 23.
3
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. Epub 2011 Nov 8.
4
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Cancer Res. 2013 Feb 15;73(4):1340-51. doi: 10.1158/0008-5472.CAN-12-1365. Epub 2012 Dec 12.
5
Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
J Cell Mol Med. 2018 Dec;22(12):6099-6111. doi: 10.1111/jcmm.13886. Epub 2018 Sep 14.
6
Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Blood. 2015 Jul 16;126(3):363-72. doi: 10.1182/blood-2014-10-604975. Epub 2015 Jun 4.
7
Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
Int J Mol Sci. 2023 Apr 13;24(8):7180. doi: 10.3390/ijms24087180.
8
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Blood. 2013 Aug 1;122(5):738-48. doi: 10.1182/blood-2012-08-447441. Epub 2013 Jun 17.
9
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Mol Cancer Ther. 2020 Aug;19(8):1636-1648. doi: 10.1158/1535-7163.MCT-19-0841. Epub 2020 May 13.
10
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Cancer Biol Ther. 2013 Oct 1;14(10):982-96. doi: 10.4161/cbt.26234. Epub 2013 Aug 22.
引用本文的文献
1
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.
Nat Rev Clin Oncol. 2025 Sep 1. doi: 10.1038/s41571-025-01068-0.
2
Cathepsin D promotes acute myeloid leukemia progression through stabilization of the anti-apoptotic proteins.
Cell Death Dis. 2025 Aug 12;16(1):611. doi: 10.1038/s41419-025-07949-7.
3
Galectin-3 Release in the Bone Marrow Microenvironment Promotes Drug Resistance and Relapse in Acute Myeloid Leukemia.
Life (Basel). 2025 Jun 10;15(6):937. doi: 10.3390/life15060937.
4
Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non-Canonical Amino Acids for Coinhibition of MCL-1 and BCL-xL in Acute Myeloid Leukemia.
Adv Sci (Weinh). 2025 Jul;12(27):e2503682. doi: 10.1002/advs.202503682. Epub 2025 Apr 30.
5
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia.
Signal Transduct Target Ther. 2025 Feb 10;10(1):50. doi: 10.1038/s41392-025-02125-x.
6
ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.
J Exp Clin Cancer Res. 2025 Jan 9;44(1):10. doi: 10.1186/s13046-024-03267-6.
7
Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia.
Int J Mol Sci. 2024 Dec 5;25(23):13091. doi: 10.3390/ijms252313091.
8
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia.
Cell Death Dis. 2024 Jun 12;15(6):413. doi: 10.1038/s41419-024-06810-7.
9
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis.
BMC Cancer. 2024 Apr 24;24(1):520. doi: 10.1186/s12885-024-12286-7.
10
Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax.
Pharmaceutics. 2024 Jan 31;16(2):209. doi: 10.3390/pharmaceutics16020209.
本文引用的文献
1
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.
Genes Dev. 2011 Aug 1;25(15):1628-40. doi: 10.1101/gad.17269211.
2
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi.
Nat Biotechnol. 2011 Jan;29(1):79-83. doi: 10.1038/nbt.1720. Epub 2010 Dec 5.
3
Mcl-1 is essential for germinal center formation and B cell memory.
Science. 2010 Nov 19;330(6007):1095-9. doi: 10.1126/science.1191793. Epub 2010 Oct 7.
4
A practical summary of site-specific recombination, conditional mutagenesis, and tamoxifen induction of CreERT2.
Methods Enzymol. 2010;477:109-23. doi: 10.1016/S0076-6879(10)77007-5.
5
The landscape of somatic copy-number alteration across human cancers.
Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.
6
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.
Nature. 2010 Jan 7;463(7277):103-7. doi: 10.1038/nature08646. Epub 2009 Dec 20.
7
The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins.
J Cell Biol. 2009 Aug 10;186(3):355-62. doi: 10.1083/jcb.200905153. Epub 2009 Aug 3.
8
AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.
Leukemia. 2009 Sep;23(9):1598-604. doi: 10.1038/leu.2009.104. Epub 2009 May 21.
9
The histone 3 lysine 4 methyltransferase, Mll2, is only required briefly in development and spermatogenesis.
Epigenetics Chromatin. 2009 Apr 6;2(1):5. doi: 10.1186/1756-8935-2-5.
10
Mouse models of human AML accurately predict chemotherapy response.
Genes Dev. 2009 Apr 1;23(7):877-89. doi: 10.1101/gad.1771409.
Zotero 插件